Novogene Clinical Laboratory
Our clinical lab is in full compliance with the Clinical Laboratory Improvement Amendments (CLIA ID Number: 05D2146243). We have implemented strict processes to regulate and control our clinical lab, such as restricted laboratory access, frequent calibration of CLIA-related laboratory equipment, and detailed documentation of various aspects of lab processes.
Our CLIA certified laboratory provides high quality genomic sequencing services with short turnaround time at a highly competitive price. Based on our clinical validation using the NovaSeq platform, Novogene achieves an average Q30 of approximately 95%, exceeding Illumina’s official guarantee of ≥ 75%. Currently, we are offering clinical grade whole exome sequencing (WES) on the NovaSeq 6000 system, with standard operating procedures fully validated in our clinical laboratory.
For more information, please contact: firstname.lastname@example.org.
- Hospitals and Integrated Delivery Networks
Transform patient care and make an impact on genetic screening and precision medicine while increasing your revenue streams with Novogene’s NGS services. From Whole Exome Sequencing to targeted panels, and beyond.
- Lab Directors and Managers
Be a part of the precision and personalized medicine revolution.
Implement highly complex genetic testing options without expensive equipment purchases, validations, or any other associated costs.
- Bioinformatics Service Providers
Expand your product offerings by having wet-lab capabilities. Be the one-stop shop for your customers without wasting any resources. Control the quality of the data you are processing by partnering directly with a sequencing provider. Set yourself apart from the crowded BI space. Your customers are looking for a single solution. Novogene can help.
- Direct to Consumer Genomics
Go beyond genotyping and array-based testing and offer your customers clinical-grade CLIA-validated NGS services with results that can be trusted. From ACMG59, to PGX, ancestry and beyond.
- Population Health Initiatives
Many healthcare organizations, IDNs, state governments, and employers are working on implementing alternative proactive health initiatives. Let us help you with the genetic disposition screening part of your project.
CLIA requires both the wet-lab portion and the dry-lab bioinformatics pipeline to be validated before the test can be used in a clinical setting. We can supply the expertise needed to tackle such a task.
Novogene’s NGS pricing is competitive enough to replace multiple panels and tests. Now is the time to implement cutting-edge next-generation sequencing into your product offerings.